VALBIOTIS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.9 EUR | -1.64% |
|
+0.91% | -22.00% |
| 26/04 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03/04 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
| Sales 2023 * | 6.63M 7.09M 592M | Sales 2024 * | 8.4M 8.98M 749M | Capitalization | 61.51M 65.77M 5.49B |
|---|---|---|---|---|---|
| Net income 2023 * | -10M -10.69M -892M | Net income 2024 * | -13M -13.9M -1.16B | EV / Sales 2023 * | 6.3 x |
| Net cash position 2023 * | 19.75M 21.12M 1.76B | Net cash position 2024 * | 18.25M 19.51M 1.63B | EV / Sales 2024 * | 5.15 x |
| P/E ratio 2023 * |
-4.17
x | P/E ratio 2024 * |
-4.53
x | Employees | 48 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.48% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.64% | ||
| 1 week | +0.91% | ||
| Current month | +7.44% | ||
| 1 month | +11.43% | ||
| 3 months | -10.55% | ||
| 6 months | -27.78% | ||
| Current year | -22.00% |
1 week
3.82
4.08
1 month
3.564.15
Current year
3.415.30
1 year
2.827.50
3 years
2.827.75
5 years
1.988.38
10 years
1.9810.65
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
Pascal Sirvent
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Sébastien Bessy
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 18/19/18 |
Laurent Lévy
CHM | Chairman | 53 | 01/17/01 |
| Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.9 | -1.64% | 42,504 |
| 25/24/25 | 3.965 | +0.89% | 36,565 |
| 24/24/24 | 3.93 | +0.13% | 8,807 |
| 23/24/23 | 3.925 | +1.29% | 54,196 |
| 22/24/22 | 3.875 | +0.26% | 9,725 |
Real-time Euronext Paris, April 26, 2024 at 09:05 pm IST
More quotes
VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. Valbiotis specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception Valbiotis has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.
Calendar
29/04/2024
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.9
EUR
Average target price
10.07
EUR
Spread / Average Target
+158.12%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.00% | 65.67M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALVAL Stock
